PTC Therapeutics, Inc.
We are a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. We are advancing a robust and diversified pipeline of transformative medicines as part of our mission to provide access to best-in-class treatments for patients with unmet medical needs.
$63.04
+$0.42 (+0.67%)
EOD Oct 22, 2026
Margins and capital returns are both well above average: 50.09% operating margin, ROIC at 216.49%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 114.5% YoY with margins expanding 87.6pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.01B
▲ +114.5% YoY
Net Income (TTM)
-$38M
▲ +287.9% YoY
Op. Margin
12.45%
▲ +87.6pp YoY
ROIC
20.89%
▲ +275.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$40M
▲ +715.1% YoY
Op. Cash Flow (TTM)
-$31M
▲ +760.4% YoY
Net Debt
-$1.53B
Net Cash Position
Cash & Equiv.
$2.23B
5Y CAGR: +35.4%
Continue Research
SourceComputed from the 10-Q filed 29 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 31 Jul 2026. How this is calculated.
Price from market data, last close as of 22 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is PTC Therapeutics (PTCT) overvalued?
PTC Therapeutics (PTCT)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, PTC Therapeutics scores 46/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is PTC Therapeutics a high-quality business?+
PTC Therapeutics scores 46 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 12.5% operating margin and a 20.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is PTC Therapeutics a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh PTCT's valuation and scores 46/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong? Check it in PTCT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PTCT
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.